Creative Biolabs, with the advanced liposomal delivery platform, aims to confront real bottlenecks researchers are running into right now.
SHIRLEY, NY, January 21, 2026 /24-7PressRelease/ — As the optimal drug delivery system for biological active agents in vitro and in vivo, liposomes attracted a lot of interest in connection with their biological and technological advantages, and it can safely be stated that they remain the most successful drug delivery system up to date. Liposomes can effectively solve the problem of non-ideal properties of drugs, such as low solubility, stability in serum, circulation half-life, biodistribution, and target tissue selectivity.
“Today, liposome research is confronted by the two common obstacles, because it is not straightforward to select appropriate lipids, and it is not easy to obtain sufficient encapsulation efficiency without negatively affecting stability,” said a researcher at Creative Biolabs.
Creative Biolabs is expandeding liposomal formulation and encapsulation services as a direct answer to this moment. Building on this expansion, the company is sharpening its capabilities across several major classes of therapeutics.
Highlighted Liposomal Formulation Development Services
• Liposomal Formulations for Proteins and Peptides
Creative Biolabs fully focuses on studying the relationship between encapsulation efficiency and phospholipid composition, buffer concentration, incubation time, incubation temperature and drug loading to provide the optimal formulation.
• Encapsulation Strategies for Small‑Molecule Drugs
Even traditional small molecules are pushing the limits of conventional delivery. Many oncology and CNS drugs are highly hydrophobic, dose‑limited by toxicity, or unable to accumulate in the right tissues. Liposomal encapsulation offers a way to improve solubility, reduce systemic exposure, and fine‑tune biodistribution.
Creative Biolabs employs two principal methods to encapsulate small molecules within liposomes—passive loading and active loading—each suited to specific types of compounds and applications. Also, they provides formulation safety evaluation services that can rigorously examine biocompatibility and potential cytotoxicity to ensure formulations meet the highest standards for research use.
• Liposome‑Based Adjuvants for Modern Vaccines
As vaccine design becomes more sophisticated, adjuvants must evolve alongside it. Liposomal adjuvants allow developers to integrate immunostimulants—such as MPLA, QS‑21, or TLR agonists—into customizable lipid structures that can shape immune responses with far greater precision. Creative Biolabs offers a complete range of liposome-based adjuvant development services, designed to meet the diverse and complex needs of modern vaccine research.
Learn more, please visit https://www.creative-biolabs.com/lipid-based-delivery/.
About Creative Biolabs
Creative Biolabs, a USA-based biotechnology company, specializes in liposome development. Equipped with talented scientists and technologies, they are confident to produce a variety of high-quality liposomes to meet the delivery of different drugs.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer:
The content on this page is syndicated from independent third-party providers. Kyrion Media makes no warranties or representations regarding the accuracy, completeness, legality, or reliability of the information, including text, images, videos, or licenses. If you are affiliated with this content or have any complaints, copyright concerns, or requests for removal, please contact us at retract@kyrionmedia.com with the specific URL of the content in question. We will review and address valid requests promptly.
